Last updated: February 22, 2026
What is NDC 68599-5804?
NDC 68599-5804 corresponds to Rifamycin SV, an antibiotic used primarily to treat mycobacterial infections, including tuberculosis. It is commercially available as part of combination therapies or as standalone medication in specific formulations.
Market Size and Demand Drivers
Current Market Landscape
- The global anti-tuberculosis (TB) drug market was valued at approximately USD 500 million in 2022.
- Rifamycin derivatives, including Rifamycin SV, constitute a significant segment, driven by the resurgence of multi-drug resistant TB (MDR-TB) and extensive use in combination therapies.
- The market growth rate is projected at 4-6% annually through 2027.
Key Factors Influencing Demand
- The increasing prevalence of TB, with an estimated 10 million cases globally in 2021 (WHO).
- Elevated incidence of MDR-TB cases requires prolonged and combination treatments, boosting demand for Rifamycin-based drugs.
- Development of new formulations and generic versions expands accessibility, influencing market penetration.
Geographic Breakdown
| Region |
Market Share (2022) |
Growth Rate (2022-2027) |
| North America |
20% |
3% |
| Europe |
15% |
4% |
| Asia-Pacific |
40% |
6% |
| Latin America |
10% |
4% |
| Africa |
15% |
5% |
Competitive Landscape
Major players manufacturing Rifamycin SV or similar derivatives include:
- Sanofi
- Pfizer
- Teva Pharmaceuticals
- Lupin Pharmaceuticals
- Mylan (now part of Viatris)
Market share is fragmented, with some companies producing generic formulations. Patent expiration timelines are critical for future market shifts.
Regulatory and Patent Status
- The original patents for Rifamycin SV expired in the early 2010s.
- Several formulations are now available as generics.
- No current major patent protections restrict manufacturing, promoting generic competition.
Price Trends and Projections
Historical Pricing Data
- The average wholesale acquisition cost (WAC) of Rifamycin SV in 2018 was approximately USD 10 per 100 mg dose.
- Prices in the United States declined by approximately 15% from 2018 to 2022 due to increased generic competition.
- In emerging markets, prices remain lower, ranging from USD 2-5 per 100 mg dose.
Price Projections (2023-2027)
| Year |
Price Range (USD per 100 mg) |
Factors Influencing Price |
| 2023 |
$2.50 - $5.00 |
Continued generic entry, price competition |
| 2024 |
$2.00 - $4.50 |
Higher volume sales, manufacturing efficiencies |
| 2025 |
$1.75 - $4.00 |
Increased manufacturing scale, potential biosimilar options |
| 2026 |
$1.50 - $3.50 |
Further generic proliferation, market saturation |
| 2027 |
$1.25 - $3.00 |
Cost reductions, market stabilization |
Key Considerations
- Price reductions are driven by increased global generic manufacturing.
- Public health initiatives may influence market stability and pricing, especially in low-income regions.
- Potential for price stabilization or slight increases if new formulations or combination products are developed.
Market Entry and Investment Outlook
- Entry barriers are low due to patent expirations and generic availability.
- Market growth hinges on TB prevalence; emerging MDR-TB hotspots in Africa and Asia sustain demand.
- Investment risk is moderate; competition is high, and price erosion continues.
Summary of Key Data
| Parameter |
Value/Projection |
| Global anti-TB drug market |
USD 500 million (2022), CAGR 4-6% through 2027 |
| NDC 68599-5804 (Rifamycin SV) |
Dominant in TB treatment, generic competition increasing |
| 2023 average price |
USD 2.50–5.00 per 100 mg dose |
| Price trend (2027) |
USD 1.25–3.00 per 100 mg dose |
| Number of manufacturers |
10+ with multiple generic producers |
Key Takeaways
- The market favors generic Rifamycin SV due to patent expirations.
- Growth is driven by TB prevalence and the rise of MDR-TB.
- Prices are declining, with potential stabilization in 2026-2027.
- Opportunities exist in emerging markets with high TB burden.
- Market competition is intense; differentiation depends on formulation and brand reputation.
FAQs
-
What factors influence the price of Rifamycin SV?
- Generic competition, manufacturing costs, regional demand, and public health policies.
-
How long will patents block new entrants?
- Most patents expired by 2012; current market comprises generics.
-
What is the main use case for NDC 68599-5804?
- Treatment of tuberculosis, especially MDR-TB, in combination with other drugs.
-
Are there emerging alternatives to Rifamycin SV?
- Yes, newer drugs like bedaquiline and pretomanid offer alternative treatments for resistant TB cases.
-
What is the risk for investors in this drug?
- Market saturation, price erosion, and regulatory changes pose moderate risks; demand remains stable in high-burden regions.
References
[1] World Health Organization. (2022). Global Tuberculosis Report 2022.
[2] IQVIA. (2022). Global Market Analysis of Anti-Tuberculosis Drugs.
[3] U.S. Food & Drug Administration. (2023). Pending and Expired Patents of Rifamycin Derivatives.
[4] Pharma Intelligence. (2023). Pricing Trends for TB Medications.
Note: This analysis is based on publicly available data and market estimates as of early 2023 and may vary depending on regional developments and regulatory changes.
